[February 16, 2018]

Gleevec (imatinib; Novartis) Drug Analysis 2018: An Orally Administered BCR-ABL Tyrosine Kinase Inhibitor (TKI) - ResearchAndMarkets.com

The "Drug analysis: Gleevec" drug pipelines has been added to ResearchAndMarkets.com's offering.

Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease.

The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.

Novartis's BCR-ABL TKI is marketed as Gleevec in the US, and Glivec outside the S for a number of different oncology indications. These include CML, acute lymphoblastic leukemia, and gastrointestinal stromal tumors.

Key Topics Covered:

List of Figures

Figure 1: Gleevec for CML - SWOT analysis

Figure 2: Drug assessment summary of Gleevec for CML

Figure 3: Drug assessment summary of Gleevec for CML

Figure 4: Gleevec - SWOT analysis in acute lymphoblastic leukemia

Figure 5: Drug assessment summary for Gleevec in acute lymphoblastic leukemia

Figure 6: Drug assessment summary for Gleevec in acute lymphoblastic leukemia

List of Tables

Table 1: Gleevec drug profile

Table 2: Gleevec pivotal trial data in CML

Table 3: Gleevec late-phase trial data in CML

Table 4: Gleevec drug profile

Table 5: Pivotal clinical trial data for Gleevec in acute lymphoblastic leukemia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vcpd59/gleevec?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180216005294/en/

[ Back To TMCnet.com's Homepage ]